KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Raw Materials (2018 - 2025)

Twist Bioscience (TWST) has disclosed Raw Materials for 8 consecutive years, with $24.7 million as the latest value for Q4 2025.

  • Quarterly Raw Materials rose 53.86% to $24.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $24.7 million through Dec 2025, up 53.86% year-over-year, with the annual reading at $20.2 million for FY2025, 16.6% up from the prior year.
  • Raw Materials for Q4 2025 was $24.7 million at Twist Bioscience, up from $20.2 million in the prior quarter.
  • The five-year high for Raw Materials was $33.6 million in Q1 2023, with the low at $11.4 million in Q1 2021.
  • Average Raw Materials over 5 years is $23.5 million, with a median of $22.9 million recorded in 2023.
  • The sharpest move saw Raw Materials surged 205.19% in 2021, then tumbled 35.92% in 2024.
  • Over 5 years, Raw Materials stood at $30.3 million in 2021, then increased by 10.62% to $33.6 million in 2022, then dropped by 29.22% to $23.8 million in 2023, then tumbled by 32.51% to $16.0 million in 2024, then surged by 53.86% to $24.7 million in 2025.
  • According to Business Quant data, Raw Materials over the past three periods came in at $24.7 million, $20.2 million, and $17.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.